LYNNETTE HOLLON: Open Payments
NPI 1629097324 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,307 in 121 payments from 26 companies in 2025. Trend: 2023 $2,335 · 2024 $2,339 · 2025 $2,307
Food & beverage: $2,307
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 14 | $257 |
| PFIZER INC. | 11 | $249 |
| AstraZeneca Pharmaceuticals LP | 14 | $241 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $227 |
| GlaxoSmithKline, LLC. | 10 | $183 |
| Novo Nordisk Inc | 9 | $161 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $137 |
| Otsuka America Pharmaceutical, Inc. | 5 | $121 |
| SANOFI-AVENTIS U.S. LLC | 3 | $73 |
| Gilead Sciences, Inc. | 3 | $72 |
Products named: JARDIANCE, MOUNJARO, Kerendia, TRELEGY ELLIPTA, REXULTI, AIRSUPRA, ELIQUIS, FARXIGA.
Industry payments across TX — which companies pay providers there.
